Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
L Amini, SK Silbert, SL Maude, LJ Nastoupil… - Nature Reviews …, 2022 - nature.com
Chimeric antigen receptor (CAR) T cells have emerged as a potent therapeutic approach for
patients with certain haematological cancers, with multiple CAR T cell products currently …
patients with certain haematological cancers, with multiple CAR T cell products currently …
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains
KM Cappell, JN Kochenderfer - Nature reviews Clinical oncology, 2021 - nature.com
Chimeric antigen receptors (CARs) are engineered proteins designed to target T cells to
cancer cells. To effectively activate the T cells in which they are expressed, CARs must …
cancer cells. To effectively activate the T cells in which they are expressed, CARs must …
[HTML][HTML] A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated
impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma …
impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma …
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm …
SJ Schuster, CS Tam, P Borchmann, N Worel… - The Lancet …, 2021 - thelancet.com
Background In the primary analysis of the pivotal JULIET trial of tisagenlecleucel, an
autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, the best overall …
autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, the best overall …
[HTML][HTML] Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow …
Background Several commercial and academic autologous chimeric antigen receptor T-cell
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma
Hematotoxicity represents a frequent chimeric antigen receptor (CAR) T-cell–related
adverse event and remains poorly understood. In this multicenter analysis, we studied …
adverse event and remains poorly understood. In this multicenter analysis, we studied …
GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany
CD19-directed chimeric antigen receptor (CAR) T cells have evolved as a new standard-of-
care (SOC) treatment in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) …
care (SOC) treatment in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) …
Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA‐1 …
Chimeric antigen receptor (CAR)‐T cell therapies have improved the outcome for many
patients with relapsed or refractory aggressive B‐cell lymphomas. In 2017, axicabtagene …
patients with relapsed or refractory aggressive B‐cell lymphomas. In 2017, axicabtagene …
[HTML][HTML] Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
M Kwon, G Iacoboni, JL Reguera, LL Corral… - …, 2023 - ncbi.nlm.nih.gov
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric
antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma …
antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma …
Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma
G Iacoboni, G Villacampa, N Martinez‐Cibrian… - Cancer …, 2021 - Wiley Online Library
Tisagenlecleucel (tisa‐cel) is a second‐generation autologous CD19‐targeted chimeric
antigen receptor (CAR) T‐cell therapy approved for relapsed/refractory (R/R) large B‐cell …
antigen receptor (CAR) T‐cell therapy approved for relapsed/refractory (R/R) large B‐cell …